Senate Bill No. 741 permits pharmacists in Oklahoma to test for and initiate drug therapy for minor, nonchronic health conditions, as defined in the bill, under a standing order from a licensed physician or medical director. The bill allows pharmacists to utilize FDA-approved or authorized tests that are CLIA-waived, while explicitly prohibiting them from testing or initiating therapy for streptococcus in individuals under six years of age. Additionally, the bill amends existing law to update various definitions related to pharmacy practice, including replacing "Board" with "State Board of Pharmacy" and clarifying the definition of "minor, nonchronic health condition" to encompass specific conditions such as influenzas and SARS-CoV-2.

Furthermore, the bill revises definitions related to drug packaging, specifically updating the definition of "unit dose package" to indicate it contains a single dose drug with required labeling information, and clarifying the definition of "unit of issue package" to refer to a package containing multiple doses of the same drug, with each dose individually separated and labeled. The bill is scheduled to take effect on November 1, 2025, following a favorable committee report from the Committee on Health and Human Services on March 3, 2025.

Statutes affected:
Introduced: 59-353.1
Floor (Senate): 59-353.1